Related Experiment Videos
Determinants of non-compliance with lipid-lowering therapy in hyperlipidemic patients
Young Sik Kim1, Sung Sunwoo, Hye Ree Lee
1Department of Family Medicine, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap-dong, Songpa-gu, Seoul, 138-736, Korea. youngkim@amc.seoul.kr
Insights
Lipid-lowering therapy compliance was low in Korean hyperlipidemic patients. Factors like young age, smoking, and lack of exercise contributed to non-compliance, alongside physician-related issues.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Hyperlipidemia is a significant risk factor for cardiovascular diseases.
- Effective management of hyperlipidemia relies on patient adherence to lipid-lowering therapies.
- Understanding non-compliance is crucial for improving treatment outcomes.
Purpose of the Study:
- To identify the determinants of non-compliance with lipid-lowering therapy in Korean hyperlipidemic patients.
- To explore patient- and physician-related factors influencing adherence to medication.
Main Methods:
- A prospective study involving 1019 hyperlipidemic Korean patients observed over 1 year.
- Regular follow-ups at 4, 12, and 24 weeks to assess compliance, measured by clinic attendance.
- Structured questionnaires administered to patients and physicians to gather data on risk factors.
Main Results:
- During the initial 24 weeks, 52.3% continued medication, 19.7% discontinued, and 28% dropped out.
- Patient factors for non-compliance included young age, smoking, lack of diet/exercise, new user status, no concomitant medication, and adverse reactions.
- Physician factors included low patient satisfaction, fewer hyperlipidemic patients seen monthly, and practice in smaller hospitals.
Conclusions:
- Compliance rates for lipid-lowering therapy were found to be relatively low in the studied population.
- Multiple patient-specific and healthcare system-related factors contribute to non-compliance, necessitating targeted interventions.
Purpose:
In order to assess the determinants of non-compliance with a lipid-lowering therapy, a prospective study of the hyperlipidemic Korean subjects was carried out.
Methods:
A total of 1019 patients was observed by 46 family physicians for the period of 1 year from January 1999 to January 2000. To ascertain the compliance associated with a lipid lowering drug (Simvastatin), we regularly followed up the hyperlipidemic patients at intervals of 4, 12 and 24 weeks. The criterion for evaluating compliance is to measure clinic attendance. Using a structured questionnaire, patients and physicians were asked about risk factors for the compliance.
Results:
During the first 24 weeks of treatment, the lipid-lowering medication was continued by 52.3% and discontinued by 19.7%. The remaining 28% dropped out. Patient-related factors for non-compliance were young age, current smoker, lack of low fat diet and exercise, new user, no concomitant medication, and occurrence of adverse reactions. Physician-related factors for non-compliance were low patients' satisfaction with the physician, small number of hyperlipidemic patients per month and working in a relatively small hospital.
Conclusions:
Compliance with the lipid-lowering therapy was relatively low and several factors for non-compliance were detected.